Reparixin is under clinical development by Dompe Farmaceutici and currently in Phase III for Community Acquired Pneumonia. According to GlobalData, Phase III drugs for Community Acquired Pneumonia have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Reparixin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Reparixin overview

Reparixin (Repertaxin) is under development to improve the efficacy of transplantation after pancreatic islet B-cell (rare) (allogenic and autologous setting) transplant, HER2 negative metastatic breast cancer, metastatic triple-negative breast cancer and liver transplantation, acute respiratory distress syndrome, pneumonia associated COVID -19 and other community-acquired pneumonia (CAP). The drug candidate is administered through oral route in the form of tablet and through intravenous infusion. It acts by targeting CXC chemokine receptors CXCR1 and CXCR2.

It was also under development for the delayed graft dysfunction after kidney transplantation, cancer related fatigue in patients with locally advanced or metastatic breast cancer, delayed graft function and primary graft dysfunction after lung transplantation.

Dompe Farmaceutici overview

Dompe Farmaceutici (Dompe) is a biopharmaceutical company that includes research and development of innovative solutions. The company product pipeline includes ophtha – NGF, NETosis – reparixin, NETosis – ladarixin and primary care – KLS-gaba. Its products treat neurotrophic keratitis, sjogren-related dry eye, back-of-the-eye, community-acquired pneumonia (CAP), acute respiratory distress syndrome (ARDS), type 1 diabetes – early onset and insulin resistant. Dompe offers its product in therapeutic areas such as pain and anti-inflammatory, cough and cold, eye, skin, oral care and cardiovascular gastro. The company has operations in the US and China. Dompe is headquartered in Milan, Italy.

For a complete picture of Reparixin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.